
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
In all campaigns to combat substance abuse by adolescents, the spotlight is usually on illicit substances—marijuana, heroin, crack, Ecstasy, or whatever else is the teenage drug-du-jour.






